Paul M. Clément

Lomustine and Bevacizumab in Progressive Glioblastoma

Wolfgang Wick, Thierry Gorlia, Martin Bendszus et al. · New England Journal of Medicine · 2017 · 978 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

Martin J. van den Bent, Alba A. Brandes, R. Rampling et al. · Journal of Clinical Oncology · 2009 · 569 citations · Full text

Medicine, Oncology, Pharmacology +17

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent et al. · The Lancet Oncology · 2016 · 498 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

Roger Stupp, Monika E. Hegi, Bart Neyns et al. · Journal of Clinical Oncology · 2010 · 443 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 397 citations · Full text

Medicine, Oncology, Pharmacology +17